D-Phenylalanine, N-[[4-(1-methylethyl)cyclohexyl]carbonyl]-, cis-

[ Molecular Formula ]:
C₁₉H₂₇NO₃

[ Molecular Weight ]:
317.42300

[ Exact Mass ]:
317.19900

[ PSA ]:
66.40000

[ LogP ]:
3.65180

[ Hazard Codes ]:
Xi

[ Risk Phrases ]:
36/37/38

[ Safety Phrases ]:
26

[ RIDADR ]:
NONH for all modes of transport

Formulation and in vitro evaluation of nateglinide microspheres using HPMC and carbopol-940 polymers by ionic gelation method.

Pak. J. Pharm. Sci. 26(6) , 1229-35, (2013)

This study involves the design and characterization of Nateglinide (NAT) microspheres to enhance patient compliance. Ionic gelation technique was used to prepare Nateglinide Microspheres by using rate...

II. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: co-milling.

Int. J. Pharm. 454(1) , 568-72, (2013)

Nateglinide is an oral antidiabetic agent that should be administered 10-30 min before the meal, but it shows low and pH-dependent solubility that may reduce its oral bioavailability. To improve nateg...

I. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: nanoparticles and co-mixing.

Int. J. Pharm. 454(1) , 562-7, (2013)

Nateglinide is a non-sulphonylurea insulinotropic oral antidiabetic agent. The main problem in formulating an oral dosage form is its low solubility in aqueous media. This problem is particularly crit...

More Articles